Rocket Pharmaceuticals, Inc. (RCKTW)

The security is trading at a fraction of a cent, significantly below its book value, which suggests the market has priced out any remaining operational viability or that the entity faces severe delisting risks. With absolutely no recent news, zero analyst coverage, and a complete lack of price history to assess trends, there is no evidence of a functioning business or a viable path to recovery. Furthermore, the absence of any dividend payments confirms this is a pure equity play with no income component. The combination of a distressed price level, total silence from the market, and no historical data to suggest a turnaround warrants a strong sell signal.